| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 213.47M | — |
| Operating expense | — | — |
| Net income | 162.85M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, PTGX returned +168.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +76.7% |
| 1 year | +168.5% |
| 5 years | +218.2% |
| 10 years | +1184.9% |
| All-time high | $154.32 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in PTGX would be worth today ›No. Protagonist Therapeutics, Inc. has not paid a dividend in the past 12 months.
Protagonist Therapeutics, Inc. stock trades on NASDAQ under the ticker symbol PTGX.
Protagonist Therapeutics, Inc. is part of the Healthcare sector.
Protagonist Therapeutics, Inc. has a market cap of 9.99B USD, based on the latest quote.
Protagonist Therapeutics, Inc. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
